Reappraising the use of β-lactams to treat tuberculosis

References

• Smith DG, Waksman SA. Tuberculostatic and tuberculocidal properties of streptomycin. J. Bacteriol. 54(2), 253–261 (1947).
   PubMed Web of Science ®Google Scholar
• Fleming A. The development and use of penicillin. Chic. Med. Sch. Q. 7(2), 20–28 (1946).
   PubMedGoogle Scholar
• Kasik JE, Weber M, Winberg E, Barclay WR. The synergistic effect of dicloxacillin and penicillin G on murine tuberculosis. Am. Rev. Respir. Dis. 94(2), 260–261 (1966).
   PubMedGoogle Scholar
• Solotorovsky M, Bugie EJ, Frost BM. The effect of penicillin on the growth of Mycobacterium tuberculosis in Dubos’ medium. J. Bacteriol. 55(4), 555–559 (1948).
   PubMedGoogle Scholar
• Kasik JE. The nature of mycobacterial penicillinase. Am. Rev. Respir. Dis. 91, 117–119 (1965).
   PubMedGoogle Scholar
• Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 99(4), 1025–1026 (1991).
   PubMed Web of Science ®Google Scholar
• Yew WW, Wong CF, Lee J, Wong PC, Chau CH. Do β-lactam–β-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tuber. Lung Dis. 76(1), 90–92 (1995).
   PubMedGoogle Scholar
• Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu. Rev. Biochem. 64, 29–63 (1995).
   PubMed Web of Science ®Google Scholar
• Ortalo-Magné A, Dupont MA, Lemassu A, Andersen AB, Gounon P, Daffé M. Molecular composition of the outermost capsular material of the tubercle bacillus. Microbiology (Reading, Engl.) 141(Pt. 7), 1609–1620 (1995).
   PubMed Web of Science ®Google Scholar
• Tipper DJ, Strominger JL. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-d-alanyl-d-alanine. Proc. Natl Acad. Sci. USA 54(4), 1133–1141 (1965).
   PubMed Web of Science ®Google Scholar
• Chambers HF, Moreau D, Yajko D et al. Can penicillins and other β-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39(12), 2620–2624 (1995).
   PubMed Web of Science ®Google Scholar
• Wietzerbin J, Das BC, Petit JF, Lederer E, Leyh-Bouille M, Ghuysen JM. Occurrence of d-alanyl-(d)-meso-diaminopimelic acid and meso-diaminopimelyl-meso-diaminopimelic acid interpeptide linkages in the peptidoglycan of mycobacteria. Biochemistry 13(17), 3471–3476 (1974).
   PubMedGoogle Scholar
• Goffin C, Ghuysen JM. Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent. Microbiol. Mol. Biol. Rev. 66(4), 702–738 (2002).
   PubMed Web of Science ®Google Scholar
• Mainardi JL, Hugonnet JE, Rusconi F et al. Unexpected inhibition of peptidoglycan ld-transpeptidase from Enterococcus faecium by the β-lactam imipenem. J. Biol. Chem. 282(42), 30414–30422 (2007).
   PubMed Web of Science ®Google Scholar
• Sifaoui F, Arthur M, Rice L, Gutmann L. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob. Agents Chemother. 45(9), 2594–2597 (2001).
   PubMed Web of Science ®Google Scholar
• Lavollay M, Arthur M, Fourgeaud M et al. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by l,d-transpeptidation. J. Bacteriol. 190(12), 4360–4366 (2008).
   PubMedGoogle Scholar
• Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43(3), 717–731 (2002).
   PubMed Web of Science ®Google Scholar
• Gupta R, Lavollay M, Mainardi JL, Arthur M, Bishai WR, Lamichhane G. The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16(4), 466–469 (2010).
   PubMed Web of Science ®Google Scholar
• Nguyen L, Thompson CJ. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol. 14(7), 304–312 (2006).
   PubMedGoogle Scholar
• Bardou F, Raynaud C, Ramos C, Lanéelle MA, Lanéelle G. Mechanism of isoniazid uptake in Mycobacterium tuberculosis. Microbiology (Reading, Engl.) 144(Pt. 9), 2539–2544 (1998).
   PubMed Web of Science ®Google Scholar
• Colangeli R, Helb D, Sridharan S et al. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol. 55(6), 1829–1840 (2005).
   PubMed Web of Science ®Google Scholar
• Stephan J, Mailaender C, Etienne G, Daffé M, Niederweis M. Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48(11), 4163–4170 (2004).
   PubMed Web of Science ®Google Scholar
• Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A β-lactamase from Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 41(5), 1182–1185 (1997).
   PubMed Web of Science ®Google Scholar
• Voladri RK, Lakey DL, Hennigan SH, Menzies BE, Edwards KM, Kernodle DS. Recombinant expression and characterization of the major β-lactamase of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42(6), 1375–1381 (1998).
   PubMedGoogle Scholar
• Flores AR, Parsons LM, Pavelka MS Jr. Genetic analysis of the β-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics. Microbiology (Reading, Engl.) 151(Pt 2), 521–532 (2005).
   PubMed Web of Science ®Google Scholar
• Coira A, Salvadó M, Reig R, Chaves J, Segura C. β-Lactamase activity in mycobacteria other than M. tuberculosis. J. Chemother. 7(2), 106–108 (1995).
   PubMed Web of Science ®Google Scholar
• Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918), 1215–1218 (2009).
   PubMed Web of Science ®Google Scholar
• Dinçer I, Ergin A, Kocagöz T. The vitro efficacy of β-lactam and β-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 23(4), 408–411 (2004).
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23(1), 160–201 (2010).
   PubMed Web of Science ®Google Scholar
• Ambler RP. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289(1036), 321–331 (1980).
   PubMed Web of Science ®Google Scholar
• Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 208(5007), 239–241 (1965).
   PubMed Web of Science ®Google Scholar
• Matthew M, Hedges RW, Smith JT. Types of β-lactamase determined by plasmids in gram-negative bacteria. J. Bacteriol. 138(3), 657–662 (1979).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4), 657–686 (2005).
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20(3), 440–458 (2007).
   PubMed Web of Science ®Google Scholar
• Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046–5054 (2009).
   PubMed Web of Science ®Google Scholar
• Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597–602 (2010).
   PubMed Web of Science ®Google Scholar
• Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18(2), 306–325 (2005).
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC β-lactamases. Clin. Microbiol. Rev. 22(1), 161–182 (2009).
   PubMed Web of Science ®Google Scholar
• Ledent P, Raquet X, Joris B, Van Beeumen J, Frère JM. A comparative study of class-D β-lactamases. Biochem. J. 292(Pt. 2), 555–562 (1993).
   PubMedGoogle Scholar
• Wang F, Cassidy C, Sacchettini JC. Crystal structure and activity studies of the Mycobacterium tuberculosis β-lactamase reveal its critical role in resistance to β-lactam antibiotics. Antimicrob. Agents Chemother. 50(8), 2762–2771 (2006).
   PubMed Web of Science ®Google Scholar
• Helfand MS, Bethel CR, Hujer AM, Hujer KM, Anderson VE, Bonomo RA. Understanding resistance to β-lactams and β-lactamase inhibitors in the SHV β-lactamase: lessons from the mutagenesis of SER-130. J. Biol. Chem. 278(52), 52724–52729 (2003).
   PubMedGoogle Scholar
• Thomas VL, Golemi-Kotra D, Kim C, Vakulenko SB, Mobashery S, Shoichet BK. Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM β-lactamase. Biochemistry 44(26), 9330–9338 (2005).
   PubMedGoogle Scholar
• Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis β-lactamase by clavulanate. Biochemistry 46(43), 11998–12004 (2007).
   PubMed Web of Science ®Google Scholar
• Tremblay LW, Hugonnet JE, Blanchard JS. Structure of the covalent adduct formed between Mycobacterium tuberculosis β-lactamase and clavulanate. Biochemistry 47(19), 5312–5316 (2008).
   PubMedGoogle Scholar
• Maveyraud L, Mourey L, Kotra L et al. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A β-lactamases from the antibiotic-resistant bacteria. J. Am. Chem. Soc. 120(38), 9748–9752 (1998).
   Google Scholar
• Zafaralla G, Mobashery, S. Facilitation of the Δ2 to Δ1 pyrroline tautomerization of carbapenem antibiotics by the highly conserved arginine 244 of class A β-lactamases during the course of turnover. J. Am. Chem. Soc. 114, 1505–1506 (1992).
   Google Scholar
• Nukaga M, Bethel CR, Thomson JM et al. Inhibition of class A β-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J. Am. Chem. Soc. 130(38), 12656–12662 (2008).
   PubMed Web of Science ®Google Scholar
• Tremblay LW, Fan F, Blanchard JS. Biochemical and structural characterization of Mycobacterium tuberculosis β-lactamase with the carbapenems ertapenem and doripenem. Biochemistry 49(17), 3766–3773 (2010).
   PubMedGoogle Scholar
• Triboulet S, Arthur M, Mainardi JL et al. Inactivation kinetics of a new target of β-lactam antibiotics. J. Biol. Chem. 286(26), 22777–22784 (2011).
   PubMedGoogle Scholar
• Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26(4), 874–877 (1998).
   PubMed Web of Science ®Google Scholar
• Donald PR, Sirgel FA, Venter A et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand. J. Infect. Dis. 33(6), 466–469 (2001).
   PubMed Web of Science ®Google Scholar
• Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49(7), 2816–2821 (2005).
   PubMed Web of Science ®Google Scholar
• Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J. 30(9), 812–813 (2011).
   PubMed Web of Science ®Google Scholar
• Veziris N, Truffot C, Mainardi JL, Jarlier V. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob. Agents Chemother. 55(6), 2597–2600 (2011).
   PubMed Web of Science ®Google Scholar
• Segura C, Salvadó M, Collado I, Chaves J, Coira A. Contribution of β-lactamases to β-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 42(6), 1524–1526 (1998).
   PubMedGoogle Scholar